WO2005099353A2 - A novel process for the preparation of linezolid and related compounds - Google Patents

A novel process for the preparation of linezolid and related compounds Download PDF

Info

Publication number
WO2005099353A2
WO2005099353A2 PCT/IN2004/000105 IN2004000105W WO2005099353A2 WO 2005099353 A2 WO2005099353 A2 WO 2005099353A2 IN 2004000105 W IN2004000105 W IN 2004000105W WO 2005099353 A2 WO2005099353 A2 WO 2005099353A2
Authority
WO
WIPO (PCT)
Prior art keywords
process according
formula
compound
solvent
reaction
Prior art date
Application number
PCT/IN2004/000105
Other languages
French (fr)
Other versions
WO2005099353A3 (en
Inventor
Dodda Mohan Rao
Pingili Krishna Reddy
Original Assignee
Symed Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35150400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005099353(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES04728229T priority Critical patent/ES2294494T3/en
Priority to EP04728229A priority patent/EP1737850B1/en
Priority to DE602004009344T priority patent/DE602004009344T2/en
Priority to PL04728229T priority patent/PL1737850T3/en
Priority to PCT/IN2004/000105 priority patent/WO2005099353A2/en
Application filed by Symed Labs Limited filed Critical Symed Labs Limited
Priority to US10/524,746 priority patent/US7307163B2/en
Publication of WO2005099353A2 publication Critical patent/WO2005099353A2/en
Publication of WO2005099353A3 publication Critical patent/WO2005099353A3/en
Priority to US11/868,608 priority patent/US7351824B2/en
Priority to US11/868,662 priority patent/US7524954B2/en
Priority to US11/868,613 priority patent/US20080021214A1/en
Priority to US11/868,633 priority patent/US7741480B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention provides a novel process for preparation of 5- aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials.
  • WO 95/07271 uses butyl lithium at very low temperature (-78°C) and WO 99/24393 uses phosgene gas. It is known that the handling of butyl lithium and phosgene gas are difficult and the person skilled in the art appreciate a process that produces the product in good yield avoiding the 'difficult to handle' reagents.
  • the present invention provides a novel process to prepare 5- aminomethyl substituted oxazolidinones of formula I:
  • X is O, S, SO or SO 2 ;
  • R- is H, CH 3 or CN;
  • R 2 is independently H, F or CI;
  • R 3 is H or CH 3 ;
  • n is 0,1 or 2; which comprises; a) reacting a compound of formula II:
  • R ⁇ R 3 , X, R 2 and n are as defined in formula I; with R-epichlorohydrin of formula
  • R 1 ⁇ R 3 , X, R 2 and n are as defined in formula I;
  • step (a) converting the product of step (a) to chloromethyl oxazolidinone compound of formula V:
  • R ⁇ R 3 , X, R 2 and n are as defined in formula I; and c) converting the chloromethyl oxazolidinone compound of step (b) to aminomethyl oxazolidinone of formula I.
  • the compounds of formula IV are novel and provides another aspect of the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION The present invention provides a novel process for preparing 5- aminomethyl substituted oxazolidinones of formula I:
  • X is O, S, SO or SO 2 ;
  • R is H, CH 3 or CN;
  • R 2 is independently H, F or CI;
  • R 3 is H or CH 3 ;
  • n is 0,1 or 2.
  • R 1 R 3 , X, R 2 and n are as defined in formula I; is reacted with R-epichlorohydrin of formula III: to provide chlorohydrin compound of formula IV:
  • R-i, R 3 , X, R 2 and n are as defined in formula I.
  • the quantity of epichlorohydrin is not critical, but for better yield at least one molar equivalent is required per equivalent of phenyl amine of formula II.
  • the reaction may be carried out with or without using a solvent. If the reaction is carried out in the absence of solvent, the compounds of formula II and the formula III are usually heated together for sufficient time to obtain the compound of formula IV.
  • the reactants are heated preferably to about 40 - 150°C and more preferably to about 40 - 120°C.
  • the time required for the conversion is 30 minutes to 10 hours, preferably 2 to 6 hours.
  • the reaction between the compounds of formula II and formula III is carried out in a solvent.
  • Any solvent, which is neutral towards the reactants, may be used.
  • Operable solvents include cyclic ethers such as tetrahydrofuran; amides such as N, N-dimethylformamide and N, N- dimethylacetamide; acetonitrile; and alcohols such as methanol, ethanol, t-amyl alcohol, t-butyl alcohol and Isopropyl alcohol; and a mixture thereof.
  • Preferable solvent is selected from methanol, isopropyl alcohol and N, N- dimethylformamide.
  • the reaction is performed at or below boiling temperature of the solvent used, more preferably between 10°C and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried.
  • the product obtained may be used directly in the next step, or it can be isolated from the reaction mixture and used in the next step.
  • the compounds of formula IV are novel and provides another aspect of the present invention.
  • Step - b) The chlorohydrin compound of formula IV produced as above is subjected to carbonylation to provide chloromethyl oxazolidinone compound of formula V:
  • R-i, R 3 , X, R 2 and n are as defined in formula I.
  • the carbonylation is performed using any carbonylating. reagent commonly known for such purpose. Among them carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate are preferred; carbonyldiimidazole being more preferred.
  • the carbonylation reaction is preferably performed by contacting the chlorohydrin compound of formula IV with carbonylating agent in the presence of an aprotic solvent or a mixture thereof.
  • the chlorohydrin compound of formula IV is reacted with at least one molar equivalent of the carbonylating agent in the presence of an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
  • an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
  • Step - c) The chloromethyl oxazolidinone compound of formula V produced as above is converted to aminomethyl oxazolidinone compound of formula I.
  • the conversion of the compound of formula V to the compound of formula I can be achieved by a method known for the conversion of aliphatic chloride to the corresponding amine.
  • chlorine atom of the chloromethyl oxazolidinone compound is first replaced by azide using azide source such as sodium azide or potassium azide to provide azide compound of formula VI:
  • R 1 ( R 3 , X, R 2 and n are as defined in formula I.
  • the azide compound is known and can be converted to the aminomethyl oxazolidinone compound by known methods such as those described in US 5,688,792.
  • the azide compound is hydrogenated using for example palladium/carbon catalyst to provide the aminomethyl oxazolidinone compound.
  • the chloromethyl oxazolidinone compound is reacted with potassium phthalimide to provide phthalimido compound of formula VII:
  • R ⁇ R 3l X, R 2 and n are as defined in formula I.
  • the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in a solvent or mixture of solvents. Selection of solvent is not critical, but preferable solvents are those that dissolve both the chloromethyl oxazolidinones and potassium phthalimide to ensure maximum contact between the reactants resulting in faster reaction. However, the process is also operable with solvents that only partially dissolve the chloromethyl oxazolidinones or potassium phthalimide.
  • the preferable solvent is dimethyl formamide or acetonitrile.
  • the reaction is performed preferably between about 10°C and the boiling temperature of the solvent used, more preferably between 40°C and 100°C and most preferably at the boiling temperature of the solvent used. Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried out. For example, if the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in dimethylformamide under reflux conditions, about 2 to
  • the phthalimido compounds of formula are known and can be converted to the aminomethyl oxazolidinone compounds by using for example Hydrazine hydrate or aqueous methylamine. These methods are known and are described for example in US 5,688,792.
  • the aminomethyl oxazolidinone compounds of formula I are acylated by known methods using acylating agents such as acyl halides or acyl anhydrides to form the corresponding 5-acylaminomethyloxazolidinone compounds of formula VIII.
  • R 1 f R 3 , X, R and n are as defined in formula I;
  • R represents C-i to C 8 straight or branched alkyl groups.
  • the preferred alkyl group is CH 3 .
  • the acylation can be carried out by known methods such as those described in US 5,688,792.
  • One compound of formula VIII can be converted to another compound of formula VIII.
  • compounds of formula VIII, wherein X is S can be converted to the compounds of formula VIII, wherein X is SO or SO 2 by the methods such as those disclosed in US 5,688, 792.
  • the 5-acyl amino methyl substituted oxazolidinone of formula VIII are known to be antibacterial pharmaceutical agents.
  • R-Epichlorohydrin has the right configuration to obtain the compounds of formula I and VIII.
  • Any solvent, which is neutral towards the reactants, may be used.
  • Operable solvents include cyclic ethers such as tetrahydrofuran; amides such as N, N-dimethylformamide and N, N-dimethylacetamide; acetonitrile; and alcohols such as methanol, ethanol, t-amyl alcohol, t-butyl alcohol and Isopropyl alcohol.
  • Preferable solvent is selected from methanol, isopropyl alcohol and N, N- dimethylformamide.
  • the reaction is performed at or below boiling temperature of the solvent used, more preferably between 10°C and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used.
  • Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried. For example, if the reaction is carried out in isopropyl alcohol solvent at the boiling temperature of the solvent, about 15 hours is required for the reaction completion.
  • the product obtained can be used directly in the next step, or it can be isolated from the reaction mixture and used in the next step.
  • carbonyldiimidazole phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate are preferred; carbonyldiimidazole being more preferred.
  • the carbonylation reaction is preferably performed by contacting the N- [3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline with carbonylating agent in the presence of an aprotic solvent or a mixture of aprotic solvents.
  • N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline is reacted with at least one molar equivalent of the carbonylating agent in the presence of an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform.
  • solvent is not critical, but preferable solvents are those that dissolve both the chloromethyl oxazolidinones and potassium phthalimide to ensure maximum contact between the reactants resulting in faster reaction.
  • the process is also operable with solvents that only partially dissolve the chloromethyl oxazolidinones or potassium phthalimide.
  • the preferable solvent is dimethyl formamide or acetonitrile.
  • the reaction is performed preferably between about 10°C and the boiling temperature of the solvent used, more preferably between 40°C and 100°C and most preferably at the boiling temperature of the solvent used. Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried out.
  • Example 5 S-N-[[3-[3-Fluoro4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] amine (20 gm) is dissolved in Ethyl acetate (200 ml), Acetic anhydride (20 gm) is added drop wise at ambient temperature and stirred for 1 hour.
  • reaction mixture is then cooled to 0-5°C, filtered the solid and re-crystallized from Isopropyl alcohol (400 ml) to give 16 gm of N-[[(5S)-3-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

Abstract

The present invention provides a novel process for preparation of 5-aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials including linezolid. Thus linezolid is prepared by a) reacting 3-fluoro-4-morpholinyl aniline with R-epichlorohydrin; b) subjecting N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline produced above to carbonylation; c) reacting (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone produced above with potassium phthalimide; d) reacting (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide produced above with hydrazine hydrate; and e) reacting S-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine produced above with acetic anhydride to produce linezolid.

Description

A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS
FIELD OF THE INVENTION The present invention provides a novel process for preparation of 5- aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials.
BACKGROUND OF THE INVENTION US Pat. No. 5,688,792 (US 5,688,792) disclosed oxazine and thiazine oxazolidinone derivatives. The compounds are antimicrobial agents. Among them linezolid, chemically N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]acetamide is the most important antibacterial agent. Linezolid is represented by the following structure:
Figure imgf000002_0001
Processes for preparation of linezolid were described in US 5,837,870, WO 99/24393, WO 95/07271 , J.Med.Chem. 39(3), 673-679, 1996 and Tetrahedron Lett., 40(26), 4855, 1999. According to prior art processes, the 5-hydroxy methyl substituted oxazolidinones are converted to the corresponding 5-aminomethyl substituted oxazolidinones, key intermediates in the production of oxazolidinone antibacterial pharmaceuticals. The prior art processes for preparing 5-aminomethyl substituted oxazolidinones are associated with many drawbacks. For instant in the preparation of linezolid, WO 95/07271 uses butyl lithium at very low temperature (-78°C) and WO 99/24393 uses phosgene gas. It is known that the handling of butyl lithium and phosgene gas are difficult and the person skilled in the art appreciate a process that produces the product in good yield avoiding the 'difficult to handle' reagents. We have discovered a novel process for preparation of 5-aminomethyl substituted oxazolidinone key intermediates using novel intermediates. The novel process solve the drawbacks associated with the prior processes and so, commercially viable for preparing these and related compounds.
SUMMARY OF INVENTION The present invention provides a novel process to prepare 5- aminomethyl substituted oxazolidinones of formula I:
Figure imgf000003_0001
wherein X is O, S, SO or SO2; R-, is H, CH3 or CN; R2 is independently H, F or CI; R3 is H or CH3; n is 0,1 or 2; which comprises; a) reacting a compound of formula II:
Figure imgf000003_0002
wherein R^ R3, X, R2 and n are as defined in formula I; with R-epichlorohydrin of formula
Figure imgf000004_0001
to produce a compound of formula IV:
Figure imgf000004_0002
wherein R1τ R3, X, R2 and n are as defined in formula I;
b) converting the product of step (a) to chloromethyl oxazolidinone compound of formula V:
Figure imgf000004_0003
wherein R^ R3, X, R2 and n are as defined in formula I; and c) converting the chloromethyl oxazolidinone compound of step (b) to aminomethyl oxazolidinone of formula I. The compounds of formula IV are novel and provides another aspect of the present invention. The compounds of the formula V with the exception of the compound of formula V wherein R = R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1 are novel. DETAILED DESCRIPTION OF THE INVENTION The present invention provides a novel process for preparing 5- aminomethyl substituted oxazolidinones of formula I:
Figure imgf000005_0001
wherein X is O, S, SO or SO2; R, is H, CH3 or CN; R2 is independently H, F or CI; R3 is H or CH3; n is 0,1 or 2.
Step - a) Phenyl amine compound of formula II:
Figure imgf000005_0002
wherein R1 ( R3, X, R2 and n are as defined in formula I; is reacted with R-epichlorohydrin of formula III:
Figure imgf000006_0001
to provide chlorohydrin compound of formula IV:
Figure imgf000006_0002
wherein R-i, R3, X, R2 and n are as defined in formula I. The quantity of epichlorohydrin is not critical, but for better yield at least one molar equivalent is required per equivalent of phenyl amine of formula II. The reaction may be carried out with or without using a solvent. If the reaction is carried out in the absence of solvent, the compounds of formula II and the formula III are usually heated together for sufficient time to obtain the compound of formula IV. The reactants are heated preferably to about 40 - 150°C and more preferably to about 40 - 120°C. The time required for the conversion is 30 minutes to 10 hours, preferably 2 to 6 hours. Preferably, the reaction between the compounds of formula II and formula III is carried out in a solvent. Any solvent, which is neutral towards the reactants, may be used. Operable solvents include cyclic ethers such as tetrahydrofuran; amides such as N, N-dimethylformamide and N, N- dimethylacetamide; acetonitrile; and alcohols such as methanol, ethanol, t-amyl alcohol, t-butyl alcohol and Isopropyl alcohol; and a mixture thereof. Preferable solvent is selected from methanol, isopropyl alcohol and N, N- dimethylformamide. The reaction is performed at or below boiling temperature of the solvent used, more preferably between 10°C and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used. Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried. The product obtained may be used directly in the next step, or it can be isolated from the reaction mixture and used in the next step. The compounds of formula IV are novel and provides another aspect of the present invention.
Step - b) The chlorohydrin compound of formula IV produced as above is subjected to carbonylation to provide chloromethyl oxazolidinone compound of formula V:
Figure imgf000007_0001
wherein R-i, R3, X, R2 and n are as defined in formula I. The carbonylation is performed using any carbonylating. reagent commonly known for such purpose. Among them carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate are preferred; carbonyldiimidazole being more preferred. The carbonylation reaction is preferably performed by contacting the chlorohydrin compound of formula IV with carbonylating agent in the presence of an aprotic solvent or a mixture thereof. More preferably the chlorohydrin compound of formula IV is reacted with at least one molar equivalent of the carbonylating agent in the presence of an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform. The compound of formula V wherein R-i = R3 is H; X is O; one R2 is H and the other R2 is F; n is 1 ((5R)-5-(chloromethyl)-3-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxazolidino ne) is mentioned in the J. Pharmaceutical and biomedical analysis, 2002, 30 (3), 635-642 as an possible impurity in linezolid. We disclosed the use of this compound and related compounds in the preparation of the compounds of formula I. The compounds of formula V, wherein X, R1 t R2, R3 and n are as defined in formula I with the exception of the compound of formula V, wherein R-i = R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1 are novel and provide another aspect of present invention.
Step - c) The chloromethyl oxazolidinone compound of formula V produced as above is converted to aminomethyl oxazolidinone compound of formula I. Preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R-, = R3 is H; R2 is independently H and F; X is O or S; and n is 1. More preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R-i = R3 is H; R2 is independently H and F; X is
O; and n is 1. Still more preferred 5-amino methyl substituted oxazolidinones are the compounds of formula I, wherein R1 = R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1. The conversion of the compound of formula V to the compound of formula I can be achieved by a method known for the conversion of aliphatic chloride to the corresponding amine. Thus, for example, chlorine atom of the chloromethyl oxazolidinone compound is first replaced by azide using azide source such as sodium azide or potassium azide to provide azide compound of formula VI:
Figure imgf000008_0001
wherein R1 ( R3, X, R2 and n are as defined in formula I. The azide compound is known and can be converted to the aminomethyl oxazolidinone compound by known methods such as those described in US 5,688,792. For example, the azide compound is hydrogenated using for example palladium/carbon catalyst to provide the aminomethyl oxazolidinone compound. Alternatively, the chloromethyl oxazolidinone compound is reacted with potassium phthalimide to provide phthalimido compound of formula VII:
Figure imgf000009_0001
wherein R^ R3l X, R2 and n are as defined in formula I. The reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in a solvent or mixture of solvents. Selection of solvent is not critical, but preferable solvents are those that dissolve both the chloromethyl oxazolidinones and potassium phthalimide to ensure maximum contact between the reactants resulting in faster reaction. However, the process is also operable with solvents that only partially dissolve the chloromethyl oxazolidinones or potassium phthalimide. The preferable solvent is dimethyl formamide or acetonitrile. The reaction is performed preferably between about 10°C and the boiling temperature of the solvent used, more preferably between 40°C and 100°C and most preferably at the boiling temperature of the solvent used. Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried out. For example, if the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in dimethylformamide under reflux conditions, about 2 to
10 hours is required for the reaction completion. The phthalimido compounds of formula are known and can be converted to the aminomethyl oxazolidinone compounds by using for example Hydrazine hydrate or aqueous methylamine. These methods are known and are described for example in US 5,688,792. The aminomethyl oxazolidinone compounds of formula I are acylated by known methods using acylating agents such as acyl halides or acyl anhydrides to form the corresponding 5-acylaminomethyloxazolidinone compounds of formula VIII.
Figure imgf000010_0001
wherein R1 f R3, X, R and n are as defined in formula I; R represents C-i to C8 straight or branched alkyl groups. The preferred alkyl group is CH3. The acylation can be carried out by known methods such as those described in US 5,688,792. One compound of formula VIII can be converted to another compound of formula VIII. Thus for example compounds of formula VIII, wherein X is S can be converted to the compounds of formula VIII, wherein X is SO or SO2 by the methods such as those disclosed in US 5,688, 792. The 5-acyl amino methyl substituted oxazolidinone of formula VIII are known to be antibacterial pharmaceutical agents. R-Epichlorohydrin has the right configuration to obtain the compounds of formula I and VIII. The configuration of epichlorohydrine is retained through out the sequence of reactions of the invention. However, it is readily apparent to one skilled in the art that one could easily perform the identical process steps with the opposite enantiomeric form or racemic form to obtain the corresponding stereo isomers. Therefore, using the chemistry of the claimed process with any of the enantiomeric forms is considered equivalent to the claimed processes. In particular most important compound of formula VIII is linezolid (VIII, R-i and R3 is H; X is O, one R2 is H and the other R2 is F; n is 1 ).
The most preferred process for preparing linezolid is described as under: a) 3-fluoro-4-morpholinyl aniline (formula II, R = R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1) is reacted with R-epichlorohydrin (formula III) to produce N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline (formula IV, R-, = R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1); The quantity of epichlorohydrin is not critical, but for better yield at least one molar equivalent is required per equivalent of 3-fluoro-4-morpholinyl aniline. Any solvent, which is neutral towards the reactants, may be used. Operable solvents include cyclic ethers such as tetrahydrofuran; amides such as N, N-dimethylformamide and N, N-dimethylacetamide; acetonitrile; and alcohols such as methanol, ethanol, t-amyl alcohol, t-butyl alcohol and Isopropyl alcohol. Preferable solvent is selected from methanol, isopropyl alcohol and N, N- dimethylformamide. The reaction is performed at or below boiling temperature of the solvent used, more preferably between 10°C and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used. Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried. For example, if the reaction is carried out in isopropyl alcohol solvent at the boiling temperature of the solvent, about 15 hours is required for the reaction completion. The product obtained can be used directly in the next step, or it can be isolated from the reaction mixture and used in the next step. b) N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline produced as above is subjected to carbonylation to provide (5R)-5-(chloromethyl)-3-[3- fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone (Formula V, R-i = R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1). The carbonylation is performed using any carbonylating reagent commonly known for such purpose. Among them carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate are preferred; carbonyldiimidazole being more preferred. The carbonylation reaction is preferably performed by contacting the N- [3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline with carbonylating agent in the presence of an aprotic solvent or a mixture of aprotic solvents. More preferably the N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline is reacted with at least one molar equivalent of the carbonylating agent in the presence of an aprotic solvent such as methylene dichloride, ethylenedichloride or chloroform. c) (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone produced as above is reacted with potassium phthalimide to provide (S)-N- [[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] phthalimide (Formula VII, R-i = R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1 ); The reaction is carried out by contacting the (5R)-5-(chloromethyl)-3-[3- fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone with potassium phthalimide in a solvent or a mixture of solvents. Selection of solvent is not critical, but preferable solvents are those that dissolve both the chloromethyl oxazolidinones and potassium phthalimide to ensure maximum contact between the reactants resulting in faster reaction. However, the process is also operable with solvents that only partially dissolve the chloromethyl oxazolidinones or potassium phthalimide. The preferable solvent is dimethyl formamide or acetonitrile. The reaction is performed preferably between about 10°C and the boiling temperature of the solvent used, more preferably between 40°C and 100°C and most preferably at the boiling temperature of the solvent used. Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried out. For example, if the reaction is carried out by contacting the 5-chloromethyl oxazolidinones with potassium phthalimide in dimethylformamide under reflux conditions, about 3 to 7 hours is required for the reaction completion. d) (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] phthalimide produced as above is reacted with hydrazine hydrate or aqueous methyl amine to produce S-N-[[3-[3-Fluoro-4-[4- morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine (Formula I, R^ = R3 is H; X is O; one R2 is H and the other R2 is F; and n is 1). These methods of deprotection are known and described for example in US 5,688,792. e) S-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine is reacted with acetic anhydride to produce linezolid. The following examples are given for the purpose of illustrating the present invention and should not be considered as limitations oh the scope and spirit of the invention. EXAMPLES Example 1 3-Fluoro-4-morpholinyl aniline (39 g) is mixed with R-epichlorohydrin (18.5 g), isopropyl alcohol (200 ml) is added and heated for 16 hours at reflux temperature. The solvent is distilled to give 57 gm of N-[3-Chloro-2-(R)- hydroxypropyl]-3-fluoro-4-morpholinyl aniline. Example 2 N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline (57 g) is dissolved in methylene dichloride (600 ml), diimidazolyl carbonyl (32 g) is added at ambient temperature and the reaction mixture is stirred for 20 hours. Then washed with water and distilled methylene dichloride to give 48 gm of (5R)-5-
(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone. Example 3 The mixture of (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxazolidinone (60 g), potassium phthalimide (40 g) and Dimethyl formamide (400 ml) is heated for 5 hours at reflux temperature. The reaction mixture is cooled to ambient temperature, poured in to 2 L water and filtered the solid to give 50 gm (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]phthalimide. Example 4 Methanol (240 ml) and Hydrazine hydrate (26 g) are added to a flask containing the (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl] methyljphthalimide (40 g), heated for 1 hour at reflux temperature and cooled to room temperature. Then water (500 ml) is added to the reaction mass and extracted with methylene dichloride (300 ml). The combined extractions were washed with water (100 ml) and the solvent distilled to give 20 gm of S-N-[[3-[3- Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] amine. Example 5 S-N-[[3-[3-Fluoro4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] amine (20 gm) is dissolved in Ethyl acetate (200 ml), Acetic anhydride (20 gm) is added drop wise at ambient temperature and stirred for 1 hour. The reaction mixture is then cooled to 0-5°C, filtered the solid and re-crystallized from Isopropyl alcohol (400 ml) to give 16 gm of N-[[(5S)-3-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

Claims

We claim:
1. A process for the preparation of 5-aminomethyl substituted oxazolidinones of formula I:
Figure imgf000015_0001
wherein X is O, S, SO or SO2;
Figure imgf000015_0002
R2 is independently H, F or CI; R3 is H or CH3; n is 0,1 or 2;
which comprises; a) reacting a compound of formula II:
Figure imgf000015_0003
wherein R-i, R3, X, R2 and n are as defined in formula I
with R-epichlorohydrin of formula III:
Figure imgf000015_0004
to produce a compound of formula IV:
Figure imgf000016_0001
wherein R1 ; R3, X, R2 and n are as defined in formula I;
b) converting the product of step (a) to chloromethyl oxazolidinone compound of formula V:
Figure imgf000016_0002
wherein R^ R3, X, R2 and n are as defined in formula I; and c) converting the chloromethyl oxazolidinone compound of step (b) to aminomethyl oxazolidinone of formula I.
2. The process according to claim 1, wherein the aminomethyl oxazolidinone formed is the compound of formula I, wherein R^Rs is H; R2 is independently H and F; X is O or S; and n is 1.
3. The process according to claim 2, wherein the aminomethyl oxazolidinone is the compound of formula I, wherein R-ι=R3 is H; R2 is independently H and F; X is O; and n is 1.
4. The process according to claim 3, wherein the aminomethyl oxazolidinone is the compound of formula I, wherein Rι=R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1.
5. The process according to claim 1 , wherein the quantity of epichlorohydrin is at least one molar equivalent per equivalent of phenyl amine of formula II.
6. The process according to claim 1 , wherein the reaction in step (a) is carried out without the use of solvent.
7. The process according to claim 6, wherein the reaction is carried out at about 40 - 150°C.
8. The process according to claim 7, wherein the reaction is carried out at about 40 - 120°C.
9. The process according to claim 1 , wherein the solvent used in step (a) is selected from the group consisting of tetrahydrofuran, N,N- dimethylformamide, N, N-dimethylacetamide, acetonitrile, methanol, ethanol, tert-amyl alcohol, t-butyl alcohol and Isopropyl alcohol.
10. The process according to claim 9, wherein the solvent is selected from methanol, isopropyl alcohol and N, -dimethylformamide.
11. The process according to claim 10, wherein the solvent is methanol.
12. The process according to claim 10, wherein the solvent is isopropyl alcohol.
13. The process according to claim 10, wherein the solvent is N,N- dimethylformamide.
14. The process according to claim 1 , wherein the reaction in the step (a) is performed at or below the boiling temperature of the solvent.
15. The process according to claim 14, wherein the reaction is performed at between 10°C and boiling temperature of the solvent.
16. A process according to claim 15, wherein the reaction is performed at boiling temperature of the solvent.
17. The process according to claim 1 , wherein the chlorohydrin compound of formula IV is subjected in the step (b) to carbonylation using a carbonylating agent to provide chloromethyl oxazolidinone compound of formula V.
18. The process according to claim 17, wherein the carbonylating reagent is selected from carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate.
19. The process according to claim 18, wherein the carbonylating reagent is carbonyldiimidazole or phosgene.
20. The process according to claim 19, wherein the carbonylating reagent is , carbonyldiimidazole.
21. The process according to claim 17, wherein the carbonylation reaction is performed in the presence of an aprotic solvent or a mixture thereof.
22. The process according to claim 21 , wherein the aprotic solvent is selected from methylenedichloride, ethylenedichloride and chloroform.
23. The process according to claim 1 , wherein the chloromethyl oxazolidinone compound of formula V is converted in the step (c) to the compound of formula I as defined in claim 1 , which comprises reacting the said chloromethyl oxazolidinone with an azide source to give an azide compound of formula VI:
Figure imgf000018_0001
wherein R-i, R3, X, R2 and n are as defined in formula I; and then reducing the said azide compound to obtain the said compound of formula I.
24. The process according to claim 23, wherein the azide source is sodium azide or potassium azide.
25. The process according to claim 23, wherein the reduction is carried out with hydrogen using palladium on carbon catalyst.
26. The process according to claim 1 , wherein the chloromethyl oxazolidinone compound of formula V is converted in the step (c) to the compound of formula I as defined in claim 1 , which comprises reacting the said chloromethyl oxazolidinone with potassium phthalimide to give phthalimido compound of formula VII:
Figure imgf000018_0002
wherein Ri, R3, X, R2 and n are as defined in formula I; and then reacting the said phthalimido compound formed with hydrazine hydrate to obtain the said compound of formula I.
27. The process according to claim 26, wherein the reaction with potassium phthalimide is carried out in presence of solvent or a mixture thereof.
28. The process according to claim 27, wherein the solvent is dimethylformamide or acetonitrile.
29. The process according to claim 27, wherein the reaction is performed between about 10°C and boiling temperature of the solvent used.
30. A process for the preparation of linezolid of formula:
Figure imgf000019_0001
which comprises: a) reacting 3-fluoro-4-morpholinyl aniline with R-epichlorohydrin to produce N- [3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline; b) subjecting N-[3-Chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline produced in step (a) to carbonylation using a carbonylating agent to provide (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone; c) reacting (5R)-5-(chloromethyl)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazoli dinone produced in step (b) with potassium phthalimide to provide (S)-N-[[3- [3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide; d) reacting (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl] methyljphthalimide produced in step (c) with hydrazine hydrate to produce S- N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]amine; and e) reacting S-N-[[3-[3-Fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl] methyljamine produced in step (d) with acetic anhydride to produce linezolid;
31. The process according to claim 30, wherein the solvent used in step (a) is selected from the group consisting of tetrahydrofuran, N,N- dimethylformamide, N, N-dimethylacetamide, acetonitrile, methanol, ethanol, tert-amyl alcohol, t-butyl alcohol and Isopropyl alcohol.
32. The process according to claim 31 , wherein the solvent used in step (a) is selected from methanol, isopropyl alcohol and N, N-dimethylformamide.
33. The process according to claim 32, wherein the solvent is methanol.
34. The process according to claim 32, wherein the solvent is isopropyl alcohol.
35. The process according to claim 30, wherein the amount of epichlorohydrin used is one molar equivalent per equivalent of 3-fluoro-4-morpholinyl aniline.
36. The process according to claim 30, wherein the reaction in the step (a) is performed at or below boiling temperature of the solvent.
37. The process according to claim 36, wherein the reaction is performed at between 10°C and boiling temperature of the solvent.
38. The process according to claim 37, wherein the reaction is performed at boiling temperature of the solvent.
39. The process according to claim 30, wherein the carbonylating reagent is selected from carbonyldiimidazole, phosgene, methyl chloroformate, benzyl chloroformate and phenylchloroformate.
40. The process according to claim 39, wherein the carbonylating reagent is carbonyldiimidazole or phosgene.
41. The process according to claim 40, wherein the carbonylating reagent is carbonyldiimidazole.
42. The process according to claim 30, wherein the carbonylation reaction in the step (b) is performed in the presence of an aprotic solvent or a mixture thereof.
43. The process according to claim 42, wherein the aprotic solvent is selected from methylenedichloride, ethylenedichloride and chloroform.
44. The process according to claim 30, wherein the step (c), the reaction is carried out in a solvent or a mixture thereof.
45. The process according to claim 44, wherein the solvent is dimethylformamide or acetonitrile.
46. The process according to claim 30, wherein the reaction is performed between about 10°C and the boiling temperature of the solvent used.
47. The process according to claim 46, wherein the reaction in the step (c) is performed between about 40°C and boiling temperature.
48. The process according to claim 47, wherein the reaction is performed at boiling temperature of the solvent used.
49. The process according to claim 30, wherein the step (d), the reaction is carried out in a solvent.
50. The process according to claim 49, wherein the solvent is selected from methanol, ethanol and isopropyl alcohol.
51. The process according to claim 30, wherein the step (e), the reaction is carried out in ethyl acetate or methylenedichloride.
52. A compound of formula IV:
Figure imgf000021_0001
wherein X is O, S, SO or SO2;
Figure imgf000021_0002
R2 is independently H, F or CI; R3 is H or CH3; n is 0,1 or 2.
53. The compound of formula IV as defined in claim 52, wherein R-|=R3 is H; R2 is independently H and F; X is O or S; and n is 1.
54. The compound of formula IV as defined in claim 53, wherein R = R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1.
55. The use of compound of formula V:
Figure imgf000022_0001
wherein X is O, S, SO or SO2;
Figure imgf000022_0002
R2 is independently H, F or CI; R3 is H or CH3; n is 0,1 or 2; for the preparation of the compounds of formula I as defined in claim I.
56. The use of the compound of formula V as defined in claim 55, wherein R^Rs is H; R2 is independently H and F; X is O or S; and n is 1.
57. The use of compound of formula V as defined in claim 56, wherein R-i = R3 is H; one R2 is H and the other R2 is F; X is O; and n is 1.
58. A compound of formula V:
Figure imgf000022_0003
wherein X is O, S, SO or SO2;
Figure imgf000022_0004
R2 is independently H, F or CI; R3 is H or CH3; n is 0,1 or 2; with the exception of the compound or formula V, wherein R-i = R3 is H; one R2 is H and the other R2 is F; X is O; and n is1.
PCT/IN2004/000105 2004-04-19 2004-04-19 A novel process for the preparation of linezolid and related compounds WO2005099353A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/524,746 US7307163B2 (en) 2004-04-19 2004-04-19 Process for the preparation of linezolid and related compounds
EP04728229A EP1737850B1 (en) 2004-04-19 2004-04-19 A novel process for the preparation of linezolid and related compounds
DE602004009344T DE602004009344T2 (en) 2004-04-19 2004-04-19 A NEW METHOD FOR THE PRODUCTION OF LINEZOLID AND RELATED COMPOUNDS
PL04728229T PL1737850T3 (en) 2004-04-19 2004-04-19 A novel process for the preparation of linezolid and related compounds
PCT/IN2004/000105 WO2005099353A2 (en) 2004-04-19 2004-04-19 A novel process for the preparation of linezolid and related compounds
ES04728229T ES2294494T3 (en) 2004-04-19 2004-04-19 A NEW PROCEDURE FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS.
US11/868,608 US7351824B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds
US11/868,662 US7524954B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds
US11/868,613 US20080021214A1 (en) 2004-04-19 2007-10-08 Novel process for the preparation of linezolid and related compounds
US11/868,633 US7741480B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000105 WO2005099353A2 (en) 2004-04-19 2004-04-19 A novel process for the preparation of linezolid and related compounds

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US10524746 A-371-Of-International 2004-04-19
US11/868,662 Division US7524954B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds
US11/868,613 Division US20080021214A1 (en) 2004-04-19 2007-10-08 Novel process for the preparation of linezolid and related compounds
US11/868,608 Division US7351824B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds
US11/868,633 Division US7741480B2 (en) 2004-04-19 2007-10-08 Process for the preparation of linezolid and related compounds

Publications (2)

Publication Number Publication Date
WO2005099353A2 true WO2005099353A2 (en) 2005-10-27
WO2005099353A3 WO2005099353A3 (en) 2006-10-26

Family

ID=35150400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000105 WO2005099353A2 (en) 2004-04-19 2004-04-19 A novel process for the preparation of linezolid and related compounds

Country Status (6)

Country Link
US (5) US7307163B2 (en)
EP (1) EP1737850B1 (en)
DE (1) DE602004009344T2 (en)
ES (1) ES2294494T3 (en)
PL (1) PL1737850T3 (en)
WO (1) WO2005099353A2 (en)

Cited By (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
US7714128B2 (en) 2003-10-16 2010-05-11 Symed Labs Limited Crystalline form of linezolid
WO2010065865A2 (en) 2008-12-05 2010-06-10 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010065824A2 (en) 2008-12-04 2010-06-10 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010071783A1 (en) 2008-12-16 2010-06-24 Abbott Laboratories Thiazoles as cannabinoid receptor ligands
WO2010083442A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010083441A2 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010092181A1 (en) 2009-02-16 2010-08-19 Abbott Gmbh & Co. Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
WO2010092180A1 (en) 2009-02-16 2010-08-19 Abbott Gmbh & Co. Kg Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2010094755A1 (en) 2009-02-20 2010-08-26 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
WO2010111572A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2243479A2 (en) 2009-04-20 2010-10-27 Abbott Laboratories Novel amide and amidine derivates and uses thereof
WO2010138828A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Potassium channel modulators
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011053740A1 (en) 2009-10-28 2011-05-05 Belkin International, Inc. Portable multi-media communication device protective carrier and method of manufacture therefor
WO2011066168A1 (en) 2009-11-25 2011-06-03 Abbott Laboratories Potassium channel modulators
WO2011068561A1 (en) 2009-12-04 2011-06-09 Abbott Laboratories Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2011068560A1 (en) 2009-12-04 2011-06-09 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011075522A1 (en) 2009-12-16 2011-06-23 Abbott Laboratories Prodrug compounds useful as cannabinoid ligands
WO2011077310A1 (en) * 2009-12-26 2011-06-30 Alembic Limited Process for the preparation of linezolid
CN102174043A (en) * 2011-02-28 2011-09-07 石药集团中诺药业（石家庄）有限公司 Method for preparing linezolid intermediate
CN101774978B (en) * 2009-01-13 2011-09-21 联化科技股份有限公司 Preparation method of linezolid and intermediate thereof
WO2011119345A2 (en) 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8058293B2 (en) 2008-03-11 2011-11-15 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2012019862A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
WO2012020134A1 (en) 2010-08-13 2012-02-16 Abbott Gmbh & Co. Kg Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012020131A2 (en) 2010-08-13 2012-02-16 Abbott Gmbh & Co. Kg Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012020130A1 (en) 2010-08-13 2012-02-16 Abbott Gmbh & Co. Kg Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012020133A1 (en) 2010-08-13 2012-02-16 Abbott Gmbh & Co. Kg Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2428507A2 (en) 2008-09-16 2012-03-14 Abbott Laboratories Cannabinoid receptor ligands
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8173687B2 (en) 2008-08-15 2012-05-08 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012067963A1 (en) 2010-11-15 2012-05-24 Abbott Laboratories Nampt inhibitors
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
WO2012067965A1 (en) 2010-11-15 2012-05-24 Abbott Laboratories Nampt and rock inhibitors
WO2012067824A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Potassium channel modulators
EP2457903A1 (en) 2008-09-08 2012-05-30 Abbott Laboratories Cannabinoid receptor ligands
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
WO2012089828A2 (en) 2010-12-30 2012-07-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8236822B2 (en) 2009-03-27 2012-08-07 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
WO2012134943A1 (en) 2011-03-25 2012-10-04 Abbott Laboratories Trpv1 antagonists
US8288428B2 (en) 2009-03-27 2012-10-16 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2012140061A1 (en) * 2011-04-11 2012-10-18 Sandoz Ag Method for the preparation of substituted oxazolidinones
WO2012152915A1 (en) 2011-05-12 2012-11-15 Abbott Gmbh & Co. Kg Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012158399A1 (en) 2011-05-13 2012-11-22 Abbott Laboratories Condensed 2 - carbamoylpyridazinones as potassium channel modulators
CN102898394A (en) * 2012-11-09 2013-01-30 重庆医科大学 Method for preparing linezolid
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013055897A1 (en) 2011-10-14 2013-04-18 Abbvie Inc. 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013055895A1 (en) 2011-10-14 2013-04-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013062966A2 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators
WO2013068470A1 (en) 2011-11-09 2013-05-16 Abbott Gmbh & Co. Kg Inhibitors of phosphodiesterase type 10a
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8501794B2 (en) 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2013120835A1 (en) 2012-02-13 2013-08-22 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8546583B2 (en) 2006-05-31 2013-10-01 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013158952A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Isoindolone derivatives
WO2013170115A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Pyridazine and pyridine derivatives as nampt inhibitors
WO2013170118A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Thiazolecarboxamide derivatives for use as nampt inhibitors
WO2013170112A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
WO2013170113A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2013177498A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Agonists of neuronal nicotinic acetylcholine receptor a7 subtype for use in the treatment of cognitive symptoms of schizophrenia
WO2013177494A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Agonists of neuronal nicotinic acetylcholine receptor a7 subtype for use in the treatment of cognitive symptoms of schizophrenia
US8604053B2 (en) 2008-10-17 2013-12-10 Abbvie Inc. TRPV1 antagonists
US8609692B2 (en) 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
WO2013188381A1 (en) 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
CN103570639A (en) * 2012-08-08 2014-02-12 成都国弘医药有限公司 Synthetic method of linezolid
WO2014041131A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
EP2613787A4 (en) * 2010-09-07 2014-04-16 Symed Labs Ltd Processes for the preparation of 4-{4-[5(s)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl} morpholin-3-one
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid
US8735434B2 (en) 2007-05-18 2014-05-27 Abbvie Inc. Compounds as cannabinoid receptor ligands
CN103864707A (en) * 2014-02-28 2014-06-18 烟台万润药业有限公司 Preparation method of (S)-[3-(3- fluoro-4-morpholinyl) phenyl-2-oxo-5-oxazolidinyl] methylamine
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
US8835475B2 (en) 2007-04-17 2014-09-16 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2014140186A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
WO2014140184A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
WO2014160028A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Pyrrolopyrimindine cdk9 kinase inhibitors
US8865753B2 (en) 2007-03-28 2014-10-21 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8906911B2 (en) 2012-04-02 2014-12-09 Abbvie Inc. Chemokine receptor antagonists
US8969375B2 (en) 2013-03-13 2015-03-03 Abbvie, Inc. CDK9 kinase inhibitors
US9006247B2 (en) 2010-05-26 2015-04-14 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9006275B2 (en) 2006-05-31 2015-04-14 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
WO2015055771A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
EP2899185A1 (en) 2010-04-30 2015-07-29 Indiana University Research and Technology Corporation Processes for preparing linezolid
WO2015119712A1 (en) 2014-02-06 2015-08-13 Abbvie Inc. Tetracyclic cdk9 kinase inhibitors
US9156788B2 (en) 2010-08-10 2015-10-13 Abbvie Inc. TRPV3 modulators
US9169253B2 (en) 2012-09-14 2015-10-27 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
WO2015173392A1 (en) 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
CN105111160A (en) * 2015-09-11 2015-12-02 浙江新东港药业股份有限公司 Linezolid preparation method
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
WO2016160938A1 (en) 2015-04-02 2016-10-06 Abbvie Inc. N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators
US9527811B2 (en) 2009-05-07 2016-12-27 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US9593104B2 (en) 2013-03-14 2017-03-14 Benova Labs Pvt. Limited Process for the preparation of oxazolidinone derivatives
US9643939B1 (en) 2016-04-18 2017-05-09 Optimus Drugs Private Limited Process for the preparation of linezolid
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9796708B2 (en) 2013-03-14 2017-10-24 Abbvie Inc. Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
WO2017193872A1 (en) 2016-05-07 2017-11-16 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2018095432A1 (en) 2016-11-28 2018-05-31 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
USRE47606E1 (en) 2016-04-21 2019-09-17 Optimus Drugs Private Limited Process for the preparation of linezolid
WO2019174598A1 (en) 2018-03-14 2019-09-19 Fochon Pharmaceuticals, Ltd. SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS
WO2019179525A1 (en) 2018-03-23 2019-09-26 Fochon Pharmaceuticals, Ltd. Deuterated compounds as rock inhibitors
EP3636651A1 (en) 2015-11-25 2020-04-15 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
US11897864B2 (en) 2009-05-26 2024-02-13 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1768967T3 (en) * 2004-07-20 2009-09-30 Symed Labs Ltd Novel intermediates for linezolid and related compounds
WO2009055423A1 (en) 2007-10-24 2009-04-30 Hmicro, Inc. Low power radiofrequency (rf) communication systems for secure wireless patch initialization and methods of use
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2012094622A2 (en) * 2011-01-07 2012-07-12 The Regents Of The University Of California Amination of aryl alcohol derivatives
PL2595968T3 (en) * 2011-02-24 2016-03-31 Lee Pharma Ltd Novel process for preparation of linezolid and its novel intermediates
CN102229577A (en) * 2011-05-11 2011-11-02 石药集团中诺药业（石家庄）有限公司 Method for preparation and purification of Linezolid intermediate
EP2753619A2 (en) * 2011-09-08 2014-07-16 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
CN103103229B (en) * 2011-11-15 2015-03-18 安琪酵母股份有限公司 Synthesis method of linezolid intermediate
WO2013105100A1 (en) * 2012-01-09 2013-07-18 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof
CN103254148B (en) 2012-02-15 2016-04-13 浙江海正药业股份有限公司 The preparation method of linezolid intermediate
CZ2012114A3 (en) 2012-02-17 2013-02-20 Zentiva, K.S. Process for preparing rivaroxaban based on saving of 1,1?-carbonyldiimidazole
WO2014170908A1 (en) * 2013-04-18 2014-10-23 Nosch Labs Private Limited Process for preparation of oxazolidinone derivatives
JP6903953B2 (en) * 2017-03-02 2021-07-14 富士フイルムビジネスイノベーション株式会社 Information processing equipment and programs
CN115925647A (en) * 2022-12-26 2023-04-07 湖北广济药业股份有限公司 Production method of linezolid

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007271A1 (en) * 1993-09-09 1995-03-16 The Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5837870A (en) * 1996-04-11 1998-11-17 Pharmacia & Upjohn Company Process to prepare oxazolidinones
WO1999024393A1 (en) * 1997-11-07 1999-05-20 Pharmacia & Upjohn Company Process to produce oxazolidinones
EP1050532A2 (en) * 1999-05-03 2000-11-08 Aerojet Fine Chemicals LLC Preparation of S,S and R,S amino acid isosteres

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029786A (en) * 1972-08-11 1977-06-14 Imperial Chemical Industries Limited Morpholine derivatives for treating depression
DE2810349A1 (en) 1978-03-10 1979-09-20 Kali Chemie Pharma Gmbh PROCESS FOR THE PREPARATION OF 3-HYDROXY-6-PHENYL-1,2,3,4-TETRAHYDRO-1,5-BENZODIAZOCINES
FR2506769A2 (en) 1978-06-09 1982-12-03 Delalande Sa Cyano:pentyl:phenyl-methoxymethyl-oxazolidinone - useful as antidepressant
US4340606A (en) 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2608604B1 (en) 1986-12-19 1989-04-28 Delalande Sa 5-HYDROXYETHYL DERIVATIVES OF OXAZOLIDINONE-2, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS
JPH09278722A (en) * 1996-02-09 1997-10-28 Pola Chem Ind Inc Optically active propanol derivative
AR027261A1 (en) 2000-02-02 2003-03-19 Upjohn Co LINEZOLID CRYSTAL FORM II
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
MY127336A (en) 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
NZ524554A (en) 2000-08-14 2005-07-29 Teva Pharma Preparation of risperidone
ES2291465T3 (en) 2001-04-20 2008-03-01 PHARMACIA & UPJOHN COMPANY LLC PROCEDURE TO PREPARE OXAZOLIDINONES.
CN1155585C (en) 2001-12-19 2004-06-30 中国医学科学院医药生物技术研究所 3,5-substituted oxazolidinone derivative and its preparing process and application
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
EP2902386B1 (en) 2003-10-16 2020-04-08 Symed Labs Limited A crystalline form of linezolid
ES2294494T3 (en) 2004-04-19 2008-04-01 Symed Labs Limited A NEW PROCEDURE FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS.
WO2006004922A1 (en) * 2004-06-29 2006-01-12 Teva Pharmaceutical Industries Ltd. Crystalline form iv of linezolid
PL1768967T3 (en) * 2004-07-20 2009-09-30 Symed Labs Ltd Novel intermediates for linezolid and related compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007271A1 (en) * 1993-09-09 1995-03-16 The Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5837870A (en) * 1996-04-11 1998-11-17 Pharmacia & Upjohn Company Process to prepare oxazolidinones
WO1999024393A1 (en) * 1997-11-07 1999-05-20 Pharmacia & Upjohn Company Process to produce oxazolidinones
EP1050532A2 (en) * 1999-05-03 2000-11-08 Aerojet Fine Chemicals LLC Preparation of S,S and R,S amino acid isosteres

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [Online] BRICKNER S.J. ET AL.: 'Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections', XP003007929 Retrieved from STN Database accession no. (1996:58412) & JOURNAL OF MEDICINAL CHEMISTRY vol. 39, no. 3, 1996, pages 673 - 679 *
DATABASE CAPLUS [Online] KRISHNA REDDY K.V.S.R. ET AL.: 'Isolation and characterization of process-related impurities in linezolid', XP003007931 Retrieved from STN Database accession no. (2002:742207) & JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS vol. 30, no. 3, 2002, pages 635 - 642 *
DATABASE CAPLUS [Online] LOHRAY B.B. ET AL.: 'A short synthesis of oxazolidinone derivatives Linezolid and Eperezolid: a new class of antibacterials', XP003007930 Retrieved from STN Database accession no. (1999:429192) & TETRAHEDRON LETTERS vol. 40, no. 26, 1999, pages 4855 - 4856 *

Cited By (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7714128B2 (en) 2003-10-16 2010-05-11 Symed Labs Limited Crystalline form of linezolid
US7718799B2 (en) 2003-10-16 2010-05-18 Symed Labs Limited Crystalline form of linezolid
US7718800B2 (en) 2003-10-16 2010-05-18 Symed Labs Limited Crystalline form of linezolid
US7741480B2 (en) 2004-04-19 2010-06-22 Symed Labs Limited Process for the preparation of linezolid and related compounds
US7351824B2 (en) 2004-04-19 2008-04-01 Symed Labs Limited Process for the preparation of linezolid and related compounds
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
US7524954B2 (en) 2004-04-19 2009-04-28 Symed Labs Limited Process for the preparation of linezolid and related compounds
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US8546583B2 (en) 2006-05-31 2013-10-01 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US9006275B2 (en) 2006-05-31 2015-04-14 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US8865753B2 (en) 2007-03-28 2014-10-21 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8835475B2 (en) 2007-04-17 2014-09-16 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8501794B2 (en) 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8735434B2 (en) 2007-05-18 2014-05-27 Abbvie Inc. Compounds as cannabinoid receptor ligands
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8058293B2 (en) 2008-03-11 2011-11-15 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8338467B2 (en) 2008-03-11 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8173687B2 (en) 2008-08-15 2012-05-08 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2546242A1 (en) 2008-09-08 2013-01-16 Abbott Laboratories Cannabinoid receptor ligands
EP2546241A1 (en) 2008-09-08 2013-01-16 Abbott Laboratories Cannabinoid receptor ligands
EP2457903A1 (en) 2008-09-08 2012-05-30 Abbott Laboratories Cannabinoid receptor ligands
US8859596B2 (en) 2008-09-16 2014-10-14 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2896615A1 (en) 2008-09-16 2015-07-22 AbbVie Bahamas Limited Cannabinoid receptor ligands
EP2428507A2 (en) 2008-09-16 2012-03-14 Abbott Laboratories Cannabinoid receptor ligands
US8188135B2 (en) 2008-09-16 2012-05-29 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8609692B2 (en) 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
US8604053B2 (en) 2008-10-17 2013-12-10 Abbvie Inc. TRPV1 antagonists
WO2010065824A2 (en) 2008-12-04 2010-06-10 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9303025B2 (en) 2008-12-04 2016-04-05 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9029404B2 (en) 2008-12-04 2015-05-12 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8952157B2 (en) 2008-12-04 2015-02-10 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9073855B2 (en) 2008-12-05 2015-07-07 Abbvie Inc. BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9045420B2 (en) 2008-12-05 2015-06-02 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9072748B2 (en) 2008-12-05 2015-07-07 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP3666758A1 (en) 2008-12-05 2020-06-17 AbbVie Inc. Process for the preparation of a sulfonamide derivative
US9315488B2 (en) 2008-12-05 2016-04-19 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010065865A2 (en) 2008-12-05 2010-06-10 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9125913B2 (en) 2008-12-05 2015-09-08 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8895592B2 (en) 2008-12-16 2014-11-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP3026046A1 (en) 2008-12-16 2016-06-01 AbbVie Inc. Thiazoles as cannabinoid receptor ligands
WO2010071783A1 (en) 2008-12-16 2010-06-24 Abbott Laboratories Thiazoles as cannabinoid receptor ligands
CN101774978B (en) * 2009-01-13 2011-09-21 联化科技股份有限公司 Preparation method of linezolid and intermediate thereof
WO2010083441A2 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010083442A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9067871B2 (en) 2009-02-16 2015-06-30 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2010092180A1 (en) 2009-02-16 2010-08-19 Abbott Gmbh & Co. Kg Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2010092181A1 (en) 2009-02-16 2010-08-19 Abbott Gmbh & Co. Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1
US9567325B2 (en) 2009-02-20 2017-02-14 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors
US8906941B2 (en) 2009-02-20 2014-12-09 Abbvie Inc. Carboxamide compounds and their use as calpain inhibitors
WO2010094755A1 (en) 2009-02-20 2010-08-26 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US8492371B2 (en) 2009-03-27 2013-07-23 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010111572A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8236822B2 (en) 2009-03-27 2012-08-07 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8288428B2 (en) 2009-03-27 2012-10-16 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2243479A2 (en) 2009-04-20 2010-10-27 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US9527811B2 (en) 2009-05-07 2016-12-27 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors
US9174982B2 (en) 2009-05-26 2015-11-03 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8580794B2 (en) 2009-05-26 2013-11-12 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US11897864B2 (en) 2009-05-26 2024-02-13 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3656771A1 (en) 2009-05-26 2020-05-27 AbbVie Ireland Unlimited Company Process for the preparation of a synthetic intermediate for apoptosis-inducing agents
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2944638A1 (en) 2009-05-26 2015-11-18 AbbVie Bahamas Limited Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9045475B2 (en) 2009-05-26 2015-06-02 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138828A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Potassium channel modulators
US8962639B2 (en) 2009-05-29 2015-02-24 Abbvie Inc. Potassium channel modulators
WO2011053740A1 (en) 2009-10-28 2011-05-05 Belkin International, Inc. Portable multi-media communication device protective carrier and method of manufacture therefor
US8629143B2 (en) 2009-11-25 2014-01-14 Abbvie Inc. Potassium channel modulators
WO2011066168A1 (en) 2009-11-25 2011-06-03 Abbott Laboratories Potassium channel modulators
WO2011068560A1 (en) 2009-12-04 2011-06-09 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011068561A1 (en) 2009-12-04 2011-06-09 Abbott Laboratories Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2011075522A1 (en) 2009-12-16 2011-06-23 Abbott Laboratories Prodrug compounds useful as cannabinoid ligands
US8536336B2 (en) 2009-12-16 2013-09-17 Abbvie Inc. Prodrug compounds useful as cannabinoid ligands
WO2011077310A1 (en) * 2009-12-26 2011-06-30 Alembic Limited Process for the preparation of linezolid
US8343967B2 (en) 2010-03-25 2013-01-01 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2757105A1 (en) 2010-03-25 2014-07-23 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011119345A2 (en) 2010-03-25 2011-09-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8188077B2 (en) 2010-03-25 2012-05-29 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9206141B2 (en) 2010-04-30 2015-12-08 Indiana University Research And Technology Corporation Processes for preparing linezolid
US9656973B2 (en) 2010-04-30 2017-05-23 Indiana University Research And Technology Corporation Processes for preparing linezolid
EP2899185A1 (en) 2010-04-30 2015-07-29 Indiana University Research and Technology Corporation Processes for preparing linezolid
US9006247B2 (en) 2010-05-26 2015-04-14 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9403822B2 (en) 2010-05-26 2016-08-02 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3312178A1 (en) 2010-05-26 2018-04-25 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
US9156788B2 (en) 2010-08-10 2015-10-13 Abbvie Inc. TRPV3 modulators
WO2012019862A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
WO2012019632A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
WO2012020131A2 (en) 2010-08-13 2012-02-16 Abbott Gmbh & Co. Kg Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012020133A1 (en) 2010-08-13 2012-02-16 Abbott Gmbh & Co. Kg Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012020130A1 (en) 2010-08-13 2012-02-16 Abbott Gmbh & Co. Kg Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012020134A1 (en) 2010-08-13 2012-02-16 Abbott Gmbh & Co. Kg Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2613787A4 (en) * 2010-09-07 2014-04-16 Symed Labs Ltd Processes for the preparation of 4-{4-[5(s)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl} morpholin-3-one
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
US10093624B2 (en) 2010-11-15 2018-10-09 Abbvie Inc. NAMPT and ROCK inhibitors
WO2012067963A1 (en) 2010-11-15 2012-05-24 Abbott Laboratories Nampt inhibitors
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
WO2012067965A1 (en) 2010-11-15 2012-05-24 Abbott Laboratories Nampt and rock inhibitors
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
WO2012067824A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Potassium channel modulators
US8609674B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
US9238649B2 (en) 2010-11-23 2016-01-19 Abbvie Inc. Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
US9840502B2 (en) 2010-11-23 2017-12-12 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US10730873B2 (en) 2010-11-23 2020-08-04 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
EP3028702A1 (en) 2010-11-23 2016-06-08 AbbVie Bahamas Limited Methods of treatment using selective bcl-2 inhibitors
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US9872861B2 (en) 2010-11-23 2018-01-23 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012089828A2 (en) 2010-12-30 2012-07-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3351543A1 (en) 2010-12-30 2018-07-25 AbbVie Deutschland GmbH & Co. KG 1-(quinolin-4-yl)-3-(6-(trifluoromethyl)-pyridin-2-yl)urea and 1-(quinolin-4-yl)-3-(6-(trifluoromethyl)-pyrazine-2-yl)urea derivatives as glycogen synthase kinase 3 (gsk-3) inhibitors for the treatment of neurodegenerative diseases
CN102174043A (en) * 2011-02-28 2011-09-07 石药集团中诺药业（石家庄）有限公司 Method for preparing linezolid intermediate
CN102174043B (en) * 2011-02-28 2013-11-13 石药集团中诺药业（石家庄）有限公司 Method for preparing linezolid intermediate
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
WO2012134943A1 (en) 2011-03-25 2012-10-04 Abbott Laboratories Trpv1 antagonists
US8802711B2 (en) 2011-03-25 2014-08-12 Abbvie Inc. TRPV1 antagonists
WO2012140061A1 (en) * 2011-04-11 2012-10-18 Sandoz Ag Method for the preparation of substituted oxazolidinones
WO2012152915A1 (en) 2011-05-12 2012-11-15 Abbott Gmbh & Co. Kg Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012158399A1 (en) 2011-05-13 2012-11-22 Abbott Laboratories Condensed 2 - carbamoylpyridazinones as potassium channel modulators
US8859549B2 (en) 2011-05-13 2014-10-14 Abbvie, Inc. Potassium channel modulators
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3266776A1 (en) 2011-10-14 2018-01-10 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013055895A1 (en) 2011-10-14 2013-04-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013055897A1 (en) 2011-10-14 2013-04-18 Abbvie Inc. 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases
US8772499B2 (en) 2011-10-24 2014-07-08 Abbvie Inc. TRPV3 modulators
WO2013062966A2 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators
WO2013062964A2 (en) 2011-10-24 2013-05-02 Abbvie Inc. Novel trpv3 modulators
US8772500B2 (en) 2011-10-24 2014-07-08 Abbvie Inc. TRPV3 modulators
WO2013068470A1 (en) 2011-11-09 2013-05-16 Abbott Gmbh & Co. Kg Inhibitors of phosphodiesterase type 10a
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013120835A1 (en) 2012-02-13 2013-08-22 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8906911B2 (en) 2012-04-02 2014-12-09 Abbvie Inc. Chemokine receptor antagonists
US9776990B2 (en) 2012-04-20 2017-10-03 Abbvie Inc. Isoindolone derivatives
WO2013158952A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Isoindolone derivatives
WO2013170115A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Pyridazine and pyridine derivatives as nampt inhibitors
US8975398B2 (en) 2012-05-11 2015-03-10 Abbvie Inc. NAMPT inhibitors
WO2013170118A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Thiazolecarboxamide derivatives for use as nampt inhibitors
WO2013170112A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
US9193723B2 (en) 2012-05-11 2015-11-24 Abbvie Inc. NAMPT inhibitors
US9187472B2 (en) 2012-05-11 2015-11-17 Abbvie Inc. NAMPT inhibitors
WO2013170113A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
US9334264B2 (en) 2012-05-11 2016-05-10 Abbvie Inc. NAMPT inhibitors
WO2013177498A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Agonists of neuronal nicotinic acetylcholine receptor a7 subtype for use in the treatment of cognitive symptoms of schizophrenia
WO2013177494A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Agonists of neuronal nicotinic acetylcholine receptor a7 subtype for use in the treatment of cognitive symptoms of schizophrenia
US9561231B2 (en) 2012-06-12 2017-02-07 Abbvie Inc. Pyridinone and pyridazinone derivatives
WO2013188381A1 (en) 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103570639B (en) * 2012-08-08 2016-02-03 成都国弘医药有限公司 A kind of synthetic method of Linezolid
CN103570639A (en) * 2012-08-08 2014-02-12 成都国弘医药有限公司 Synthetic method of linezolid
US9994568B2 (en) 2012-09-14 2018-06-12 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
WO2014041131A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
US10118926B2 (en) 2012-09-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
US9169253B2 (en) 2012-09-14 2015-10-27 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid
CN102898394A (en) * 2012-11-09 2013-01-30 重庆医科大学 Method for preparing linezolid
US9650358B2 (en) 2013-03-13 2017-05-16 Abbvie Inc. Pyridine CDK9 kinase inhibitors
US8969375B2 (en) 2013-03-13 2015-03-03 Abbvie, Inc. CDK9 kinase inhibitors
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
EP3415514A1 (en) 2013-03-14 2018-12-19 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9593104B2 (en) 2013-03-14 2017-03-14 Benova Labs Pvt. Limited Process for the preparation of oxazolidinone derivatives
US9073922B2 (en) 2013-03-14 2015-07-07 Abbvie, Inc. Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
WO2014160028A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Pyrrolopyrimindine cdk9 kinase inhibitors
WO2014140184A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9796708B2 (en) 2013-03-14 2017-10-24 Abbvie Inc. Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
WO2014140186A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055771A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
WO2015119712A1 (en) 2014-02-06 2015-08-13 Abbvie Inc. Tetracyclic cdk9 kinase inhibitors
CN103864707B (en) * 2014-02-28 2015-11-04 烟台万润药业有限公司 (S)-[3-(the fluoro-4-morpholinyl of 3-) phenyl-2-oxo-5-oxazolidinyl] methylamine preparation method
CN103864707A (en) * 2014-02-28 2014-06-18 烟台万润药业有限公司 Preparation method of (S)-[3-(3- fluoro-4-morpholinyl) phenyl-2-oxo-5-oxazolidinyl] methylamine
WO2015173392A1 (en) 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016160938A1 (en) 2015-04-02 2016-10-06 Abbvie Inc. N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators
CN105111160B (en) * 2015-09-11 2017-04-12 浙江新东港药业股份有限公司 Linezolid preparation method
CN105111160A (en) * 2015-09-11 2015-12-02 浙江新东港药业股份有限公司 Linezolid preparation method
EP3636651A1 (en) 2015-11-25 2020-04-15 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
US9643939B1 (en) 2016-04-18 2017-05-09 Optimus Drugs Private Limited Process for the preparation of linezolid
USRE47606E1 (en) 2016-04-21 2019-09-17 Optimus Drugs Private Limited Process for the preparation of linezolid
WO2017193872A1 (en) 2016-05-07 2017-11-16 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2018095432A1 (en) 2016-11-28 2018-05-31 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
EP4119560A1 (en) 2017-04-18 2023-01-18 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
WO2019174598A1 (en) 2018-03-14 2019-09-19 Fochon Pharmaceuticals, Ltd. SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS
WO2019179525A1 (en) 2018-03-23 2019-09-26 Fochon Pharmaceuticals, Ltd. Deuterated compounds as rock inhibitors

Also Published As

Publication number Publication date
WO2005099353A3 (en) 2006-10-26
US20080021213A1 (en) 2008-01-24
US20070032472A1 (en) 2007-02-08
EP1737850A2 (en) 2007-01-03
US7351824B2 (en) 2008-04-01
PL1737850T3 (en) 2008-02-29
US7741480B2 (en) 2010-06-22
EP1737850B1 (en) 2007-10-03
ES2294494T3 (en) 2008-04-01
DE602004009344T2 (en) 2008-07-10
DE602004009344D1 (en) 2007-11-15
US20080021215A1 (en) 2008-01-24
US7524954B2 (en) 2009-04-28
US20080027219A1 (en) 2008-01-31
US20080021214A1 (en) 2008-01-24
US7307163B2 (en) 2007-12-11

Similar Documents

Publication Publication Date Title
EP1737850B1 (en) A novel process for the preparation of linezolid and related compounds
EP1768967B1 (en) Novel intermediates for linezolid and related compounds
US6613944B2 (en) Process to produce 3-carbon amino alcohol salts
EP1328509B1 (en) Methods of producing oxazolidinone compounds
EP2595968A1 (en) Novel process for preparation of linezolid and its novel intermediates
WO2010084514A2 (en) A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
CN1308319C (en) Process for synthesis of HTV protease inhibitors
EP3250568A1 (en) An improved process for the preparation of linezolid
AU2007205740A1 (en) Methods of producing oxazolidinone compounds
JPH10251234A (en) Imidazolidine oxides and production of the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 797/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007032472

Country of ref document: US

Ref document number: 10524746

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004728229

Country of ref document: EP

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 2004728229

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10524746

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004728229

Country of ref document: EP